MILDRONATS EU 250mg 40caps (heart and brain support)

MILDRONAT® (Meldonium, THP, MET-88, Mildronats, Quaterine) is an anti-ischemic drug developed for treatment of heart ischemia and its consequences. Mildronate is used in neurology for the treatment of brain circulation disorders. It significantly improves patients' mood. They become more active, their motor dysfunction decreases, and asthenia, dizziness and nausea become less pronounced. The drug also improves the learning abilities and memory.

The active substance of the drug is meldonium. The action of the drug is to prevent accumulation of cytotoxic intermediate products of fatty acid beta-oxidation in ischemic tissues and to block this highly oxygen-consuming process. Mildronate has a beneficial effect on cerebral circulation disorders and central nervous system functions. Mildronate is prescribed for patients with decreased working efficiency.

Usage:

• improves oxygen delivery to cells,
• excellent for sportsmen to improve stamina,
• protects cells from intoxication,
• improves energy levels and faster physical recovery,
• treat chronic heart failure and cerebral strokes,
• abstinence syndrome.

Ingredients:

Active substance: meldonium posphate 250mg

Dosage:

Mildronate comes in capsules.

• As part of combined therapy: 500-1000 mg once a day (or divide the daily dose for 2 times a day). Period of therapy is 4-6 weeks.
• Chronic disorders of cerebral circulation: 500 mg once a day. Period of therapy is 4-6 weeks.
• Intellectual and physical stress: 250 mg four times a day. Period of therapy is 10-14 days.
• Sportsmen: 500-1000 mg two times a day before training. Duration of treatment during preparatory period is 2-3 weeks, during the period of competition 10-14 days.
• Chronic alcoholism: 500 mg four times a day. Period of therapy is 7-10 days.

Since January 1, 2016, meldonium has been included in the list of prohibited substances of the World Anti-Doping Agency.

Form release:

250 mg/cap, 40 caps

Guaranteed authenticity and quality:

100% Original from  GRINDEX (Latvia. EU)

GRINDEKS is the leading pharmaceutical manufacturer in the Baltic States, operating since 1946. Grindeks Group consists of 4 subsidiaries with manufacturing facilities in Latvia, Estonia and Slovakia. Grindeks manufactures high quality active pharmaceutical ingredients and final dosage forms, providing our patients and partners with safe and modern products.

Development and production:

GRINDEX (Latvia. EU)